ZA988924B - Therapeutics for hepatic diseases - Google Patents

Therapeutics for hepatic diseases

Info

Publication number
ZA988924B
ZA988924B ZA988924A ZA988924A ZA988924B ZA 988924 B ZA988924 B ZA 988924B ZA 988924 A ZA988924 A ZA 988924A ZA 988924 A ZA988924 A ZA 988924A ZA 988924 B ZA988924 B ZA 988924B
Authority
ZA
South Africa
Prior art keywords
hepatic
hepatic diseases
caused
active ingredient
compositions
Prior art date
Application number
ZA988924A
Other languages
English (en)
Inventor
Susumut Satomi
Hideyuki Doi
Masahiro Chin
Hiromichi Komatsu
Hiroshi Koga
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ZA988924B publication Critical patent/ZA988924B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ZA988924A 1997-09-30 1998-09-30 Therapeutics for hepatic diseases ZA988924B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26579397 1997-09-30

Publications (1)

Publication Number Publication Date
ZA988924B true ZA988924B (en) 1999-03-30

Family

ID=17422126

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988924A ZA988924B (en) 1997-09-30 1998-09-30 Therapeutics for hepatic diseases

Country Status (11)

Country Link
EP (2) EP1025844B1 (zh)
KR (2) KR20010030820A (zh)
CN (1) CN1149988C (zh)
AT (1) ATE336241T1 (zh)
AU (1) AU9280298A (zh)
CA (1) CA2305206A1 (zh)
DE (1) DE69835609T2 (zh)
HK (1) HK1033275A1 (zh)
TW (1) TW473387B (zh)
WO (1) WO1999016433A1 (zh)
ZA (1) ZA988924B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6726200A (en) * 1999-08-23 2001-03-19 Chugai Seiyaku Kabushiki Kaisha Remedies for liver regeneration of transplanted liver
TW200626080A (en) 2000-10-13 2006-08-01 Chugai Pharmaceutical Co Ltd Food compositions comprising valine for improving lipid metabolism
WO2003063853A1 (fr) * 2002-01-31 2003-08-07 Chugai Seiyaku Kabushiki Kaisha Compositions de reduction de la graisse mesenterique
CN102458417B (zh) * 2009-06-24 2015-02-25 味之素株式会社 核酸类似物的活性增强剂
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668374A (en) * 1979-11-08 1981-06-09 Jun Sawada Food composition for hepatic insufficiency
JPS61186320A (ja) * 1985-02-12 1986-08-20 Morishita Seiyaku Kk アミノ酸製剤
JP2618653B2 (ja) * 1987-09-22 1997-06-11 ルセル森下株式会社 肝性脳症患者用アミノ酸製剤
EP0605742A4 (en) * 1992-06-26 1996-01-03 Nonna Dmitrievna Kislyakova Agent with adaptogenic activity.
ATE289809T1 (de) * 1994-06-23 2005-03-15 Chugai Pharmaceutical Co Ltd Verwendung von valin zur herstellung eines medikaments zur leberregeneration

Also Published As

Publication number Publication date
DE69835609T2 (de) 2007-08-09
HK1033275A1 (en) 2001-08-24
CN1149988C (zh) 2004-05-19
KR100562739B1 (ko) 2006-03-20
EP1025844A1 (en) 2000-08-09
EP1714649A2 (en) 2006-10-25
TW473387B (en) 2002-01-21
WO1999016433A1 (fr) 1999-04-08
DE69835609D1 (de) 2006-09-28
EP1025844B1 (en) 2006-08-16
EP1714649A3 (en) 2007-09-05
CN1278168A (zh) 2000-12-27
KR20010030820A (ko) 2001-04-16
EP1025844A4 (en) 2002-10-02
ATE336241T1 (de) 2006-09-15
KR20050054921A (ko) 2005-06-10
CA2305206A1 (en) 1999-04-08
AU9280298A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
MXPA01007666A (es) Granulos a base de almidon y de lactosa.
FI844364L (fi) Produkt, som kan foeraendras.
NO992463D0 (no) N-(aryl/heteroarylacetyl)aminosyreestere, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptidfrigivelse og/eller dens syntese ved bruk av slike forbindelser
EP0402755A3 (de) L-Carnitin-Magnesium-Zitrat
ZA988924B (en) Therapeutics for hepatic diseases
EP0841017A3 (en) A sports footwear structure, particularly for in-line roller skates
PT1095061E (pt) Péptidos baseados na sequência da lactoferrina humana e sua utilização
CA2332915A1 (en) Compositions comprising gaba analogs and caffeine
CA2020663A1 (en) Substitution analogues of magainin peptides
CA2212904A1 (en) The activity-inhibitor and activity-potentiator for glutamic acid in the brain
DK0948328T3 (da) Sammensætninger baseret på aminosyrer
US5378722A (en) Nutritional compositions for management of nitrogen metabolism
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
BG103543A (en) The use of pramipexol in the treatment of the uneasy legs syndrome
AU8530891A (en) 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases
NZ228208A (en) Eglin compounds (hurudin) and protease inhibitor pharmaceutical compositions
GR3036574T3 (en) Pharmaceutical compositions comprising hirudin
WO1997012527A3 (de) Verwendung von threonin zur behandlung der phenylketonurie
WO2004000870A3 (en) Two synthetic peptides for treatment and prevention of cancers
CA2203228A1 (en) Gluten lactose blends
Zhang et al. Primary structure of myohemerythrin from Phascolopsis gouldii
Skalska-Hilgier et al. Effect of intoxication with furfural on rat tissue aspartate aminotransferase and rat tissue alanine aminotransferase.
ES8502611A1 (es) Un procedimiento para preparar composiciones farmaceuticas a base de sales de teofilina y aminoacidos basicos
BG51857A1 (en) Product for sportsmen feeding
郭翔 et al. Enhancement of (-)-stepholidine on protein phosphorylation of adopamineand cAMP-regulated phosphoprotein in denervated striatum of oxidopaminelesioned rats